Skip to main content
Michael Andreeff, MD, Hematology, Houston, TX

Michael Andreeff MD PhD

Hematology•Houston, TX

Hematologic Oncology

Professor of Medicine, Haas Chair in Genetics, Chief, Molecular Hematology and Therapy, U.T. MD Anderson Cancer Center

Join to View Full Profile

  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Dr. Andreeff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Andreeff's Full ProfileAlready have an account?

Summary

  • Dr. Michael Andreeff is a Houston-based specialist in Hematology with a subspecialty in Hematologic Oncology. He completed his medical degree at the University of Heidelberg Faculty of Medicine in 1968 and earned his Ph.D. in Cell Biology from the University of Heidelberg Medical School. His areas of expertise include hematologic oncology, myelodysplasia, and Acute Myeloid Leukemias. He has been a pioneer in Flow Cytometry and has developed numerous agents which are now in Leukemia therapy, including G-CSF, Sorafenib, Venetoclax, MDM2- and IAP- and menin-inhibitors, as well first-in-class MYC/GSPT1 degraders.. Dr. Andreeff has authored >800 publications, including pre-clinical and clinical studies on the therapy of myeloid and lymphoid leukemias. He also developed a pioneering technology for the therapy of solid tumors involving gene-modified mesenchymal stem cells, that convert immunologically "cold" into "hot" tumors.

Education & Training

  • University of Heidelberg Medical School
    University of Heidelberg Medical SchoolPh.D., Cell Biology, 1971 - 1976
  • University of Heidelberg Faculty of Medicine
    University of Heidelberg Faculty of MedicineClass of 1968

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 1991 - 2027

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
    Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
  • NSG-S Mice for Acute Myeloid Leukemia, Yes. For Myelodysplastic Syndrome, No  
    Michael Andreeff, MD, Haematologica
  • PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in Cancer  
    Michael Andreeff, Marina Konopleva, Nature

Abstracts/Posters

  • Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
    Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
    Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
    Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Diverse Landscape of TET2 Variants in MDS and AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
  • MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
  • The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

  • MD Anderson Research Highlights for May 8, 2025
    MD Anderson Research Highlights for May 8, 2025May 8th, 2025
  • Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach?
    Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach?April 30th, 2025
  • New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
    New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18th, 2024
  • Join now to see all

Grant Support

  • Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
  • Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
  • Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
  • Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AMLUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2024

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Michael Andreeff, Dr. Michael Andreeff, MD, Dr. M Andreeff